

Amendment

In the Claims:

Please cancel claims 24, 26 and 31 without prejudice and disclaimer.

Please amend claims 1, 9, 25, 27 and 29 as follows:

ε<sup>1</sup> 1. (Twice amended) A keratinocyte growth factor fragment [comprising a portion of an amino acid sequence of mature, full-length keratinocyte growth factor, wherein the fragment] that exhibits at least a 2-fold increase in mitogenic activity as compared to a mature, recombinant, full-length keratinocyte growth factor, [and] wherein the fragment lacks [a sequence comprising] the first 23 N-terminal amino acid residues of the mature, full-length keratinocyte growth factor but retains the remainder of the molecule.

7 59. (Twice amended) A ~~therapeutic~~ composition comprising:

ε<sup>2</sup> (a) a keratinocyte growth factor fragment that [comprises a portion of an amino acid sequence of mature, full-length keratinocyte growth factor, wherein the portion] exhibits at least a 2-fold increase in mitogenic activity as compared to the mature, recombinant, full-length keratinocyte growth factor, wherein the fragment [but] lacks [a sequence comprising] the first 23 N-terminal amino acid residues of the mature, full-length keratinocyte growth factor but retains the remainder of the molecule, and

7 (b) a ~~pharmaceutically acceptable~~ carrier.

ε<sup>3</sup> 7 25. (Amended) An analog of the keratinocyte growth factor fragment as claimed in claim [24] 34<sup>6</sup>, wherein the analog <sup>differs from the keratinocyte growth factor fragment of claim 34 in having</sup> at least one conservative substitution selected from the group of substitutions consisting of a

*ε3*  
*word.*  
substitution of a leucine with an isoleucine or an isoleucine with a leucine, a substitution of a leucine with a valine or a valine with a leucine, a substitution of an aspartic acid with a glutamic acid or a glutamic acid with an aspartic acid and a substitution of a threonine with a serine or a serine with a threonine [of an amino acid with a structurally related amino acid] and further wherein the analog exhibits the biological activity of the keratinocyte growth factor fragment.

*ε4* 7 *differs from 24 keratinocyte growth factor fragment of claim 34 in having*  
B27. (Amended) An analog of the keratinocyte growth factor fragment as claimed in claim [24] <sup>34,6</sup> wherein the analog has at least one cysteine residue substituted by another amino acid and further wherein the analog exhibits the biological activity of the keratinocyte growth factor fragment.

*ε5* 7 <sup>29,10</sup>  
29. (Amended) A ~~therapeutic~~ composition comprising:

- 7  
(a) the keratinocyte growth factor fragment as claimed in claim [24] <sup>34,6</sup> and  
(b) a ~~pharmaceutically acceptable~~ carrier.

Please add the following new claim:

*ε6* 7  
--34. (New) The keratinocyte growth factor fragment as <sup>0</sup>claimed in claim 1 having the amino acid sequence depicted at amino acid residues 24 to 163, inclusive, of Figure 1. *(Amino Acid Residues 55-174, inclusive, of SEQ ID NO:1)*

Remarks

Introductory Comments:

Claims 1-4, 9 and 24-33 were examined in the Office Action dated December 7, 1995 (Paper No. 17), and rejected

*602*